Endothelial S100A1 modulates vascular function via nitric oxide

Circulation Research

Volumn 102, Issue 7, 2008, Pages 786-794

  Pleger, Sven T ^a,c   Harris, David M ^b   Shan, Changguang ^c   Vinge, Leif E ^a,e   Chuprun, J Kurt ^a   Berzins, Brett ^a   Pleger, Wiebke ^a   Druckman, Charles ^b   Völkers, Mirko ^c   Heierhorst, Jörg ^f   Øie, Erik ^d   Remppis, Andrew ^c   Katus, Hugo A ^c   Scalia, Rosario ^a   Eckhart, Andrea D ^b   Koch, Walter J ^a   Most, Patrick ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Calcium; Endothelial function; Hypertension; NO; S100A1; Vascular function

Indexed keywords

2 AMINOETHOXYDIPHENYLBORANE; ACETYLCHOLINE; CALCIUM; CALCIUM BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; S100A1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; HEART FAILURE; HYPERTENSION; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; THORACIC AORTA; VASCULAR DISEASE; WILD TYPE;

EID: 42049093998     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.172031     Document Type: Article

References (36)

1. Most P, Koch WJ. S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Future Cardiol. 2007;3:5-11.
2. Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol. 2007;293:R568-R577.
3. Pleger ST, Boucher M, Most P, Koch WJ. Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. J Card Fail. 2007;13:401-414.
4. Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch WJ, Aebi U, Schoenenberger CA. Ca2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol. 2007;27:4365-4373.
5. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Boerries M, Niroomand F, Pieske B, Janssen PM, Eschenhagen T, Karczewski P, Smith GL, Koch WJ, Katus HA, Remppis A. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A. 2001;20:98:13889-13894.
6. Most P, Boerries M, Eicher C, Schweda C, Ehlermann P, Pleger ST, Löffler E, Koch WJ, Katus HA, Schoenenberger CA, Remppis A. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular-regulated kinase (ERK1/2) pathway. J Biol Chem. 2003;278:48404-48412.
7. Most P, Remppis A, Pleger ST, Löffler E, Ehlermann P, Bernotat J, Kleuss C, Heierhorst J, Ruiz P, Witt H, Karczewski P, Mao L, Rockman HA, Duncan SJ, Katus HA, Koch WJ. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem. 2003;5:278:33809-33817.
8. Most P, Remppis A, Weber C, Bernotat J, Ehlermann P, Pleger ST, Kirsch W, Weber M, Uttenweiler D, Smith GL, Katus HA, Fink RH. The C-terminus (aa 75-94) and the linker region (aa 42-54) of the Ca2+ binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibres. J Biol Chem. 2003;278:26356-26364.
9. Remppis A, Pleger ST, Most P, Lindenkamp J, Ehlermann P, Schweda C, Löffler E, Weichenhan D, Zimmermann W, Eschenhagen T, Koch WJ, Katus HA. S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med. 2004;6:387-394.
10. Völkers M, Loughrey CM, Macquaide N, Remppis A, DeGeorge BR Jr, Wegner FV, Friedrich O, Fink RH, Koch WJ, Smith GL, Most P. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium. 2007;41:135-143.
11. Remppis A, Greten T, Schäfer BW, Hunziker P, Erne P, Katus HA, Heizmann CW. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta. 1996;11:1313:253-257.
12. Most P, Pleger ST, Völkers M, Heidt B, Boerries M, Weichenhan D, Löffler E, Janssen PM, Eckhart AD, Martini J, Williams ML, Katus HA, Remppis A, Koch WJ. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004;114:1550-1563.
13. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, Gao E, Dasgupta A, Rengo G, Remppis A, Katus HA, Eckhart AD, Rabinowitz JE, Koch WJ. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007;15:115:2506-2515.
14. Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, Pleger ST, DeGeorge B, Feldman AM, Koch WJ. Cardiac S100A1 protein levels determine contractile performance and propensity towards heart failure after myocardial infarction. Circulation. 2006;19:114:1258-1268.
15. Lefranc F, Decaestecker C, Brotchi J, Heizmann CW, Dewitte O, Kiss R, Mijatovic T. Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-beta, -eta and -zeta) in a rat model of cerebral basilar artery vasospasm. Neuropathol Appl Neurobiol. 2005;31:649-660.
16. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;23:78:915-918.
17. Sessa WC. eNOS at a glance. Cell Sci. 2004;15:117:2427-2429.
18. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1-R12.
19. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
20. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60.
21. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;25:111:310-314.
22. Du XJ, Cole TJ, Tenis N, Gao XM, Kontgen F, Kemp BE, Heierhorst J. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol. 2002;22:2821-2829.
23. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, Arcucci O, Pastore L, Salvatore F, Condorelli G, Trimarco B. AKT participates in endothelial dysfunction in hypertension. Circulation. 2004;1:109:2587-2593.
24. Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI. Isolation of endothelial cells from murine tissue. J Immunol Methods. 2000;20:244:205-215.
25. Stalker TJ, Gong Y, Scalia R. The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes. 2005;54:1132-1140.
26. Pleger ST, Remppis A, Heidt B, Völkers M, Chuprun JK, Kuhn M, Zhou RH, Gao E, Szabo G, Weichenhan D, Müller OJ, Eckhart AD, Katus HA, Koch WJ, Most P. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther. 2005;12:1120-1129.
27. Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T, Sollner S, Katus HA, Remppis A, Aebi U, Koch WJ, Schoenenberger CA. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci. 2005;15:118:421-431.
28. Eckhart AD, Ozaki T, Tevaearai H, Rockman HA, Koch WJ. Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates β adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol. 2002;61:749-758.
29. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol. 2005;90:449-455.
30. Fleming I, Kohlstedt K, Busse R. The tissue renin-angiotensin system and intracellular signalling. Curr Opin Nephrol Hypertens. 2006;15:8-13.
31. Polyakov AA, Huber PA, Marston SB, Gusev NB. Interaction of isoforms of S100 protein with smooth muscle caldesmon. FEBS Lett. 1998;422:235-239.
32. Kettlewell S, Most P, Currie S, Koch WJ, Smith GL. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol. 2005;39:900-910.
33. Liu LH, Paul RJ, Sutliff RL, Miller ML, Lorenz JN, Pun RY, Duffy JJ, Doetschman T, Kimura Y, MacLennan DH, Hoying JB, Shull GE. Defective endothelium-dependent relaxation of vascular smooth muscle and endothelial cell Ca2+ signaling in mice lacking sarco(endo)plasmic reticulum Ca2+-ATPase isoform 3. J Biol Chem. 1997;28:272:30538-30545.
34. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;23:392:821-824.
35. Okada M, Hatakeyama T, Itoh H, Tokuta N, Tokumitsu H, Kobayashi R. S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90 multichaperone complex. J Biol Chem. 2004;279:4221-4233.
36. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23:374-380.